The US Food and Drug Administration (FDA) has approved a fixed-dose combination (FDC) of aclidinium bromide 400 μg and formoterol fumarate 12 μg for treating chronic obstructive pulmonary disease (COPD). The dosage to be administered is twice daily via a traditional inhaler. Mode of Action: Aclidinium bromide It is a type of anticholinergic which acts as a long-acting muscarinic antagonist receptor (LAMA) used for long-term management of COPD. It binds with muscarinic receptors to relieve bronchospasm assisting in taking down COPD associated chronic bronchitis and emphysema.
It works its action by binding with five muscarinic receptor subtypes located in smooth muscle, thereby effecting airways to cause bronchodilation. Mode of Action: Formoterol fumarate It is long-acting beta2-agonist (LABA) used for the management of COPD or asthma. It works by tranquillizing smooth muscles in the…
